These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 1988134)

  • 1. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
    O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
    Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical investigation of benzisoquinolinedione.
    Legha SS; Ring S; Raber M; Felder TB; Newman RA; Krakoff IH
    Cancer Treat Rep; 1987 Dec; 71(12):1165-9. PubMed ID: 3690526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical investigation of amonafide.
    Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
    J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
    Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
    Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
    Rowinsky EK; Burke PJ; Karp JE; Tucker RW; Ettinger DS; Donehower RC
    Cancer Res; 1989 Aug; 49(16):4640-7. PubMed ID: 2568175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of amonafide dosing based on acetylator phenotype.
    Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB
    Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
    Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
    Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
    Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
    Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
    Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.